

10/505231

DT09 Rec'd PCT/PTO 19 AUG 2006

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Paul Richard Gellert
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-724

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JDA	AA	US-4,344,934	08-17-1982	Martin et al.	
JDA	AB	US-US 2003/0045537-A1	03-06-2003	Lee et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
JDA	BA	-WO 96/33980	10-31-1996	Gibson		
JDA	BB	-GB 2,306,885	05-14-1997	Poile		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Anderson/	Date Considered	07/18/2006
--------------------	------------------	-----------------	------------

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary) PTO Form 1449			Attorney Docket No. <b>056291-5174-US</b>		Application No. <b>10/505,231</b>			
			Applicants: <b>GELLERT et al.</b>				<b>PAGE 1 of 2</b>	
			Filing Date: <b>August 19, 2004</b>			Group Art Unit: <b>1615</b>		

OIP E  
 JUL 28 2005  
 RECEIVED

U.S. PATENT DOCUMENTS						
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
<div style="font-size: 2em;">↓</div>	JDA 1.	2003/045537	March 6, 2003	Lee et al.		
	2.	2002/009494	January 24, 2002	Curatolo et al.		
	3.	6,383,471	May 7, 2002	Chen et al.		
	4.	6,294,192	September 25, 2001	Patel et al.		
	5.	6,248,771	June 19, 2001	Shenoy et al.		
	6.	5,631,248	May 20, 1997	Davis et al.		
	7.	5,616,582	April 1, 1997	Barker		
	8.	5,559,158	September 24, 1996	Al-Razzak et al.		
	9.	5,457,105	October 10, 1995	Barker		
	10.	4,704,284	November 3, 1987	Beatty et al.		
	JDA 11.	4,344,934	August 17, 1982	Martin et al.		

FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-Class	Translation
<div style="font-size: 2em;">↓</div>	JDA 12.	WO 03/32956	April 24, 2003	WIPO		
	13.	WO 03/00294	January 3, 2003	WIPO		
	14.	WO 02/89773	November 14, 2002	WIPO		
	15.	WO 02/20020	March 14, 2002	WIPO		
	16.	WO 02/02534	January 10, 2002	WIPO		
	17.	WO 01/76586	October 18, 2001	WIPO		
	18.	WO 01/47495	July 5, 2001	WIPO		
	19.	WO 01/04102	January 18, 2001	WIPO		
	20.	WO 00/59475	October 12, 2000	WIPO		
	21.	WO 00/00179	January 6, 2000	WIPO		
	22.	WO 98/38984	September 11, 1998	WIPO		
	23.	WO 96/38131	December 5, 1996	WIPO		
	24.	WO 96/33980	October 31, 1996	WIPO		
	25.	EP 1027887	August 16, 2000	EPA		
	26.	EP 1027886	August 16, 2000	EPA		
	27.	EP 901786	March 17, 1999	EPA		
	JDA 28.	GB 2,306,885	May 14, 1997	Great Britain		
	JDA 29.	JP 09059159	March 4, 1997	Japan		Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
JDA	30. Barker et al. "Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" Bioorg Med Chem Lett. 11(14): 1911-1914 (2001)
JDA	31. Hasegawa et al. "Supersaturation mechanism of drugs from solid dispersions with enteric coating agents" Chem Pharm Bull (Tokyo) 36(12): 4941-4950 (1988)
JDA	32. Herbst et al. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial" J Clin Oncol 20(18): 3815-3825 (2002)

Examiner <b>/James Anderson/</b>	Date Considered <b>07/18/2006</b>
----------------------------------	-----------------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b>PTO Form 1449</b>				Attorney Docket No. <b>056291-5174-US</b>		Application No. <b>10/505,231</b>			
				Applicants: <b>GELLERT <i>et al.</i></b>				<b>PAGE 2 of 2</b>	
				Filing Date: <b>August 19, 2004</b>		Group Art Unit: <b>1615</b>			

  

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	

  

FOREIGN PATENT DOCUMENTS							
Document No.	Date	Country	Class	Sub-Class	Translation		

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
JDA	33.	Iervolino et al. "Membrane penetration enhancement of ibuprofen using supersaturation" Int. J. Pharm. 198: 229-238 (2000)					
	34.	Iervolino et al. "Penetration enhancement of ibuprofen from supersaturated solutions through human skin" Int. J. Pharm. 212: 131-141 (2001)					
	35.	Ikeda et al. Chem. Pharm. Bull., 42(11): 2320-2326 (1994)					
	36.	Lawrence et al. "Small-molecule tyrosine kinase inhibitors as radiosensitizers" Seminars in Radiation Oncology 12(3): 33-36 (2002)					
	37.	Loftsson et al. "The effect of water-soluble polymers on aqueous solubility of drugs" Int. J. Pharm. 127: 293-296 (1996)					
	38.	Magne et al. "New cytotoxic and molecular-targeted therapies of head and neck tumors" Current Opinion in Oncology 16(3): 225-230 (2004)					
	39.	Megrab <i>et al.</i> "Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation" J. Control Rel 36: 277-294 (1995)					
	40.	Moser et al. "Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery" Int. J. Pharm. 224: 169-176 (2001)					
	41.	Pellett <i>et al.</i> "The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro" J. Control Release 46: 205-214 (1997)					
	42.	Raghavan et al. "Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate" Int. J. Pharm. 193(2): 231-237 (2000)					
	43.	Ranson et al. "ZD1839, a Selective Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial" Journal of Clinical Oncology 20(9): 2240-2250 (2002)					
V	44.	Usui et al. "Inhibitory Effects of Water-Soluble Polymers on Precipitation of RS-8359" Int. J. Pharm. 154: 59-66 (1997)					
JDA	45.	Wakeling et al. "An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy" Cancer Research 62: 5749-5754 (2002)					

  

Examiner <div style="text-align: center;">/James Anderson/</div>	Date Considered <div style="text-align: center;">07/18/2006</div>
---	--

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.